Compare Gold Fields Limited (GFI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Johnson & Johnson — how do they compare? Gold Fields Limited trades at $37.01 (market cap $31.87B), while Johnson & Johnson trades at $260.9 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 19.4× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (6%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Johnson & Johnson for 129 Days on average.
| GFI | JNJ | |
|---|---|---|
Market Cap | $31.87B | $618.09B |
Volume | 4,169,651 | 6,050,983 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $278.43 |
52-Week Low | $31.25 | $186.00 |
Typical Hold Time | 49 Days | 129 Days |
Enterprise Value | $32.47B | $646.37B |
Dividend Yield | 6% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.70, up 4.71% over 24 hours, but technical indicators signal a bearish trend with price near support at $35. The company reported strong 2025 results with revenue of $8.75 billion and net income of $3.57 billion, yielding high profitability margins. However, recent earnings misses and a rejected $27 billion takeover bid for Northern Star have introduced volatility. Analyst consensus remains positive with a $52.75 price target, but the stock faces headwinds from acquisition-related uncertainty and mixed technical signals.
GFI presents a compelling value case with low P/E of 7.3 and robust cash flow growth, but investors must weigh execution risks from its aggressive M&A strategy and recent earnings inconsistencies against its strong fundamentals and shareholder returns. The stock's near-term direction hinges on merger outcomes and gold price stability.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
